GlassScriptPhysician profile
Morton Hantman
NPI 1265468136
$8,781.53
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,889 · 2020: $1,248 · 2021: $1,719 · 2022: $1,886 · 2023: $1,401 · 2024: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.61 |
| Education | $173.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,011.28 | 2019-2023 | Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $746.30 | 2019-2024 | |
| Incyte Corporation | $637.72 | 2019-2024 | Jakafi |
| Janssen Biotech, INC. | $518.70 | 2019-2024 | Imbruvica, Darzalex |
| Lilly USA, LLC | $422.53 | 2019-2023 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $418.93 | 2019-2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $403.62 | 2019-2023 | Opdivo |
| Rigel Pharmaceuticals, INC. | $354.16 | 2019-2023 | Rezlidhia, Tavalisse |
| Pfizer INC. | $319.53 | 2019-2023 | |
| Seagen INC. | $278.90 | 2019-2023 | Tukysa, Adcetris |
| Celgene Corporation | $268.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $257.48 | 2019-2023 | Keytruda, Lynparza |
| Teva Pharmaceuticals USA, INC. | $201.37 | 2019-2021 | |
| Genentech USA, INC. | $201.08 | 2019-2023 | Venclexta |
| Celltrion USA INC. | $196.86 | 2023-2024 | Vegzelma |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morton Hantman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.